Global Cardiopulmonary Devices Market valued at $2.8 billion in 2021, is projected to witness a decent growth of 5% by 2026

Cardiopulmonary diseases include a wide range of medical conditions that affect the heart and lungs. Cardiopulmonary devices include heart-lung machines (HLM), percutaneous ventricular assist devices (PVAD), extracorporeal membrane oxygenation (ECMO) & Autotransfusion (ATS). These devices find usage in cardiac surgeries, pulmonary surgeries, congenital defects, cardiopulmonary bypass procedures, cardiogenic shock/respiratory failure, joint replacement surgeries, aneurysm surgeries, transplants, and other indications.

Impact of Covid-19 Pandemic on the Cardiopulmonary Devices Market

During 2020-2021, most of the patients infected with the Covid-19 virus showcased moderate symptoms and recovered quickly. However, some patients developed severe respiratory failure and required intensive care unit (ICU) admission and mechanical ventilation. To save the lives of these severe Covid-19 patients, ECMO emerged as a promising option. The ECMO machine supports both the heart and lungs and stabilizes patients to allow their bodies more time to fight the virus.

Growing awareness about ECMO, HLM & other cardiopulmonary devices and the implementation of new ECMO centers during the COVID-19 pandemic further boosted the growth of the global cardiopulmonary devices market.

Regulatory Policies in Major Markets Boosts the Cardiopulmonary Devices Market

To fight the Covid-19 virus and to offer cardiopulmonary and advanced circulatory support products and therapies that may benefit Covid-19 virus-infected patients. In April 2020, the FDA permitted manufacturers of cardiopulmonary bypass devices to modify the product indications for use to include ECMO therapy for greater than six hours, without prior submission of a premarket notification to FDA. The favourable regulatory policy change resulted in increased sales of cardiopulmonary and advanced circulatory support products.

“ECMO has emerged as a game-changer for Covid-19 patients. It has proven to be a life saver. More than 200 patients at our hospital who have been on ECMO longer than 24 hours have recovered.”-Director, Mechanical Circulatory Support & ECMO, Leading Hospital, USA

Technological Advancements Fuels the Cardiopulmonary Devices Market

The global cardiopulmonary devices market is a technology-driven market and is marked by constant product innovations. For instance,

• In April, 2022, LivaNova initiates the targeted commercial launch of the Essenz??Patient Monitor for cardiopulmonary bypass procedures. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures.

Growth Strategies Adopted by Key Players to Establish Their Foothold in Cardiopulmonary Devices Market

The global cardiopulmonary devices market is marked by the presence of both established and new players. Players operating in the market have adopted both organic and inorganic growth strategies such as acquisitions, and new product launches to garner higher market share. For instance,

• In February 2022, Getinge acquired 100% of the equity interest in Talis Clinical LLC, a US-based leading innovator of High Acuity cloud-based software solutions. Talis Clinical’s offer is designed to support and document care throughout the general and cardiac perioperative care process, but also through labor and delivery episodes and critical care support including ECMO Therapy.

Competitive Landscape Analysis: Cardiopulmonary Devices Market

The cardiopulmonary devices market is marked by the presence of top market players such as LivaNova, Getinge, Terumo, Medtronic, Abbott, Abiomed, Haemonetics, Fresenius, among others.

Get Customized Research Report on Cardiopulmonary Devices Market @ https://meditechinsights.com/cardiopulmonary-devices-market/